{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06354465",
            "orgStudyIdInfo": {
                "id": "IRB1967355"
            },
            "secondaryIdInfos": [
                {
                    "id": "K23DA055695",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/K23DA055695"
                }
            ],
            "organization": {
                "fullName": "Lifespan",
                "class": "OTHER"
            },
            "briefTitle": "Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews",
            "officialTitle": "Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews",
            "therapeuticArea": [
                "Other"
            ],
            "study": "injectable-extended-release-buprenorphine-xr-b-in-a-correctional-setting-qualitative-interviews"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-07-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-31",
            "studyFirstSubmitQcDate": "2024-04-04",
            "studyFirstPostDateStruct": {
                "date": "2024-04-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Justin Berk",
                "investigatorTitle": "Assistant Professor",
                "investigatorAffiliation": "Lifespan"
            },
            "leadSponsor": {
                "name": "Lifespan",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a feasible and effective alternative to the standard daily treatment and to identify which groups within the prison population may benefit the most from this treatment. In-depth interviews are conducted with incarcerated individuals and relevant stakeholders."
        },
        "conditionsModule": {
            "conditions": [
                "Opioid Use Disorder",
                "Criminal Justice",
                "Treatment Adherence and Compliance"
            ],
            "keywords": [
                "addiction",
                "criminal justice",
                "Medications for opioid use disorder"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "CROSS_SECTIONAL"
            },
            "enrollmentInfo": {
                "count": 25,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Incarcerated Individuals",
                    "description": "Incarcerated individuals will be recruited across the Rhode Island Department of Corrections (RIDOC)facility during the required group sessions for treatment; this is consistent with previous NIH-funded studies at RIDOC. The interviews will be described and participants will be able to sign up confidentially. Participants who are eligible for Medications for Opioid Use Disorder (MOUD) but decide not to pursue treatment will still be interviewed to provide better understanding of the key factors that drive program participation. These individuals can be recruited through routine clinical care by addiction medicine providers. Every precaution will be taken to ensure confidentiality and protection of all participants."
                },
                {
                    "label": "Stakeholders",
                    "description": "Organizational stakeholders (clinicians, Wardens, leadership and/or other staff) will be recruited through snowball sampling. I will individually approach leaders of each facility to recruit correctional individuals interested in participating and will also allow participants to confidentially sign up at administrative meetings related to Medication for Addiction Treatment (MAT)."
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Qualitative Transcripts",
                    "description": "A directed content analysis will identify key themes in structured interviews",
                    "timeFrame": "1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Incarcerated individuals, inclusion criteria:\n\n* English speaking\n* Over the age of 18\n* Diagnosed with opioid use disorder\n\nIncarcerated individuals, Exclusion Criteria:\n\n- Diagnosed with \"Severe, Persistent, Mental Illness (SPMI)\" Rationale for Exclusion: These individuals suffer from severe mental health disease and therefore warrant greater protection, have greater risk for coercion, and offer insights to severe co-diagnosis treatment that, while important, remain outside the scope of general MAT implementation.\n\nOrganizational Stakeholders, Inclusion Criteria:\n\n- Employed or contracted by Rhode Island Department of Corrections (for organizational staff interviews) and involved with the Medication for Addiction Treatment (MAT) program\n\nOrganizational Stakeholders, Exclusion Criteria:\n\n- If not permitted by their organizational union to participate",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Incarcerated individuals include participants in the RIDOC MOUD program.\n\nOrganizational stakeholders inlcude clinicians, Wardens, leadership and/or other staff involved in the MOUD program.",
            "samplingMethod": "PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Justin Berk, MD",
                    "role": "CONTACT",
                    "phone": "8064333960",
                    "email": "justin_berk@brown.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Justin Berk, MD",
                    "affiliation": "Lifespan",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Rhode Island Department of Corrections",
                    "status": "RECRUITING",
                    "city": "Cranston",
                    "state": "Rhode Island",
                    "zip": "02920",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jessica Migliaccio",
                            "role": "CONTACT",
                            "phone": "401-462-3921",
                            "email": "doc.planning@doc.ri.gov"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.77982,
                        "lon": -71.43728
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED",
            "description": "Given the sensitivity of data, some individual data may be censored but will be available to other researchers in aggregate."
        }
    },
    "documentSection": {
        "largeDocumentModule": {
            "largeDocs": [
                {
                    "typeAbbrev": "Prot",
                    "hasProtocol": true,
                    "hasSap": false,
                    "hasIcf": false,
                    "label": "Study Protocol",
                    "date": "2023-10-09",
                    "uploadDate": "2024-03-31T17:37",
                    "filename": "Prot_000.pdf",
                    "size": 125769
                },
                {
                    "typeAbbrev": "ICF",
                    "hasProtocol": false,
                    "hasSap": false,
                    "hasIcf": true,
                    "label": "Informed Consent Form",
                    "date": "2023-01-07",
                    "uploadDate": "2024-04-04T09:46",
                    "filename": "ICF_001.pdf",
                    "size": 488632
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009293",
                    "term": "Opioid-Related Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000079524",
                    "term": "Narcotic-Related Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19100",
                    "name": "Behavior, Addictive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12244",
                    "name": "Opioid-Related Disorders",
                    "asFound": "Opioid Use Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2057",
                    "name": "Narcotic-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M5317",
                    "name": "Buprenorphine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "NarcAntag",
                    "name": "Narcotic Antagonists"
                }
            ]
        }
    },
    "hasResults": false
}